People with hemophilia A do not have enough of a protein found naturally in the blood called "clotting factor 8", also known as FVIII. This protein helps the blood to clump together to prevent and stop bleeding. People with lower levels of FVIII or FVIII that does not work properly may bleed for a long time from minor wounds, bleed into their joints, or have internal bleeding. The study treatment, Jivi (also called damoctocog alfa pegol), is already available as a treatment for people aged 12 years and older with hemophilia A, to help prevent bleeding, also known as "prophylactic" treatment. It works by replacing the missing FVIII, or the FVIII that does not work properly. It can also be used to stop bleeding that has already occurred and prior to surgery to prevent bleeding. The main goal of this study is to learn how damoctocog alfa pegol is used in the "real world" as a treatment in the United States (US) and how well it works and what other treatments patients use while receiving damoctocog alfa pegol treatment. It will also determine how satisfied people are with the treatment. There will be no required visits with a study doctor in this study. The study will include about 20 male or female patients in the US aged 12 years and over who have hemophilia A. All the patients in this study will have switched from their previous FVIII replacement treatment to damoctocog alfa pegol. While the patients are receiving damoctocog alfa pegol, they will complete a survey to say how they feel about the treatment. Their doctors will also record information about their treatment with damoctocog alfa pegol and how well it is working. This study will collect information from the patients' medical records and surveys. They will use this information to find out more about treatment with damoctocog alfa pegol under "real world" conditions. They will look at: * how often the patients receive damoctocog alfa pegol and how much they use * what other treatments the patients received before receiving damoctocog alfa pegol, how they used it and how much they used * how well damoctocog alfa pegol works at preventing bleeding, and how it compares to previous products used.
Study Type
OBSERVATIONAL
Enrollment
14
Retrospective analysis using database without any intervention assigned in the study.
University of California, Davis
Sacramento, California, United States
Tulane University
New Orleans, Louisiana, United States
Regents of the University of Minnesota
Minneapolis, Minnesota, United States
Frequency of damoctocog alfa pegol infusions
Reported as infusions. IRB: institutional review board
Time frame: From index date through the date of central IRB approval (3 years and 8 months)
Descriptive summary of pre-damoctocog alfa pegol treatment regimen
Time frame: 6 months prior to the index date.
Descriptive summary of damoctocog alfa pegol treatment regimen.
Time frame: Up to 5 years from index date
Descriptive summary of post-damoctocog alfa pegol treatment regimen, if applicable.
Only applicable for patients who discontinue damoctocog alfa pegol treatment regime.
Time frame: Up to 4 years
Descriptive summary of changes in pre-damoctocog alfa pegol treatment regimes
Time frame: 6 months prior to the index date.
Descriptive summary for reasons for treatment discontinuation of pre-damoctocog alfa pegol treatment regimes.
Time frame: 6 months prior to the index date.
Annualized number of spontaneous, joint, and trauma bleeds before initiation of treatment with damoctocog alfa pegol.
Time frame: 6 months prior to the index date.
Annualized number of spontaneous, joint, and trauma bleeds post initiation of treatment with damoctocog alfa pegol.
Time frame: Up to 5 years from index date
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.